Feed / NBIX

Neurocrine Biosciences, Inc.

NBIX

Healthcare · 152.52 -0.3% today

Partial group confirmationMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

Neurocrine Biosciences, Inc.'s move is being confirmed by its market group.

NBIX accounts for 11.9% of the group's measured movement across 7.8 effective names. raw member direction is mixed; 6 of 12 SPY-adjusted paths align to the downside. Capital-flow agreement is 41%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

SPY-adjusted 5m paths
Role in the moveAligned contributor#4 of 12 by movement share
Group movement share11.9%Absolute path energy—not portfolio weight
Relative path-0.82%aligned
Effective breadth7.8 / 12broad
Relative alignment6/12downside path · 4 counter-moving
Capital-flow agreement41%not yet clean
SEQUENCE READ

ACAD, EXEL, BMY moved materially before NBIX. NBIX crossed its material path threshold at 11:40 ET, 60 minutes after the first measured mover. BMRN, REGN, HALO followed.

What changed
  • Revenue increased 42.2% versus the comparable filing period.
EVIDENCE COVERAGE

8 of 15 members in Biopharmaceuticals and Care are active. 0 of 8 disclosed connections are confirming.

What would change this read
  • At least 10 of 15 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as ABBV begins moving with the group.

Invalidation: The live read weakens if participation falls to 5 of 15 members or fewer.

Watch this read

Who this business touches

The relationships behind NBIX

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

ABBVAbbVie Inc.partnerFeb 11, 2026 ▾

“Our partner AbbVie received FDA approval for ORILISSA for endometriosis in July 2018 and for ORIAHNN for uterine fibroids in May 2020.”

TAKTakeda Pharmaceutical Company LimitedpartnerFeb 11, 2026 ▾

“Some of our other collaborators include Nxera Pharma UK Limited (formerly Sosei Heptares), Takeda Pharmaceutical Company Limited, Voyager Therapeutics, Inc., and Xenon Pharmaceuticals Inc.”

Depended on by

XENEXenon Pharmaceuticals Inc.partnerMay 7, 2026 ▾

“Our Partnered Program with Neurocrine Biosciences In December 2019, we entered into a license and collaboration agreement with Neurocrine Biosciences to develop treatments for epilepsy.”

Filing peers

RYTMBIOAGPCR

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 13 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

NBIX is currently a Participant in the organic co-movement group Biopharmaceuticals and Care. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.